video (9:15 min) Outcome of ovarian cancer patients was significantly improved with niraparib. ESMO 2016 Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, October 08, 2016

video (9:15 min) Outcome of ovarian cancer patients was significantly improved with niraparib. ESMO 2016



(9:15 min) video

Dr Mansoor Raza Mirza - Copenhagen University Hospital, Copenhagen, Denmark
Dr Raza Mirza presents, at a press conference at ESMO 2016, the results of the ENGOT-OV16/NOVA trial.

They found that the PARP inhibitor niraparib significantly improved the outcome of platinum-sensitive recurrent ovarian cancer.
The trial met its primary endpoint, with niraparib considerably prolonging progression-free survival compared to placebo.
Read the news story or watch the interview for more.

0 comments :

Post a Comment

Your comments?